Dark

DNLI
Denali Therapeutics Inc. Common Stock
stock NASDAQ

At Close

Aug 6, 2026 3:59:56 PM EDT

24.76USD+1.413%(+0.34)3,049,179

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 5, 2026 9:21:30 AM EDT

24.10USD-1.310%(-0.32)0

After-hours

Aug 6, 2026 4:36:30 PM EDT

25.10USD+1.353%(+0.34)1,430

OverviewOptionsHistoricalExchangesShortsNews

Jan 23, 2022

11:52AM EST Pomerantz LLP is investigating claims on behalf of investors of Denali Therapeutics Inc. (Denali or the Company) (NASDAQ:DNLI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Jan 13, 2022

02:35PM EST Mid-Afternoon Market Update: Nasdaq Dips 250 Points; Taiwan Semiconductor Shares Gain Benzinga

11:50AM EST Mid-Morning Market Update: Markets Rise; Delta Air Lines Profit Tops Estimates Benzinga

11:46AM EST Denali Therapeutics Announces FDA Clinical Hold On DNL919 Investigational New Drug Application Benzinga

08:00AM EST Denali Therapeutics Announces FDA Clinical Hold on DNL919 GlobeNewswire Inc

Jan 10, 2022

08:00AM EST Denali Therapeutics Announces Progression and Expansion of Broad GlobeNewswire Inc

Jan 6, 2022

10:30AM EST Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $91 Benzinga

Nov 17, 2021

08:31AM EST Denali Therapeutics Announces Strategic Partner Takeda Exercises Option To Co-Develop And Co-Commercialize DNL593 Benzinga

08:30AM EST Companies to advance clinical development of DNL593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN) GlobeNewswire Inc

Nov 5, 2021

09:21AM EDT Denali Therapeutics Q3 EPS $(0.69) Down From $(0.54) YoY, Sales $5.28M Down From $9.39M YoY Benzinga

Oct 13, 2021

10:12AM EDT Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize PR Newswire

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

06:52AM EDT Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program Benzinga

Oct 6, 2021

04:03PM EDT UPDATE: Denali Says Sanofi Will Begin Phase 2 Study For Amyotrophic Lateral Sclerosis In Q1'22 Benzinga

04:02PM EDT Denali Therapeutics Reports Results, Regulatory Progress For Development Programs In Amyotrophic Lateral Sclerosis: Achieved Safety, Biomarker Goals Benzinga

04:01PM EDT Denali Therapeutics Announces Positive Clinical Results and GlobeNewswire Inc

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 3, 2021

02:21PM EDT The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More Benzinga

Sep 29, 2021

09:04AM EDT Denali Therapeutics Announces Upcoming Presentations On EIF2B Activator DNL343 And RIPK1 Inhibitor SAR443820/DNL788 At 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting Oct. 6 Benzinga

09:00AM EDT -- Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343 -- Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820 -- Denali to host analyst and investor webinar on October 6, at 4:30 p.m. Eastern Time GlobeNewswire Inc

Sep 27, 2021

09:01AM EDT Denali Therapeutics Names Katie Peng As CFO Benzinga

09:00AM EDT Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced the appointment of GlobeNewswire Inc

Sep 21, 2021

10:33AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021 Benzinga

05:19AM EDT Oppenheimer Initiates Coverage On Denali Therapeutics with Outperform Rating, Announces Price Target of $85 Benzinga

Sep 9, 2021

09:04AM EDT Denali Therapeutics Announces Initiation Of Phase 1b Study Of EIF2B Activator DNL343 in ALS Benzinga

09:00AM EDT Denali Therapeutics Announces Initiation of Phase 1b Study of GlobeNewswire Inc

Aug 26, 2021

11:00AM EDT Denali Therapeutics Announces Publication in Cell on New Approach GlobeNewswire Inc

Aug 16, 2021

08:38AM EDT Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $99 Benzinga

Aug 4, 2021

04:29PM EDT Denali Therapeutics Q2 EPS $(0.50) Up From $(0.56) YoY, Sales $22.94M Up From $5.85M YoY Benzinga

04:01PM EDT Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2021, and provided business highlights. GlobeNewswire Inc

Jul 26, 2021

09:38AM EDT HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $105 Benzinga

06:59AM EDT Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome Benzinga

Jul 25, 2021

11:05AM EDT Denali Therapeutics Announces Positive Interim Data from Phase 1/2 GlobeNewswire Inc

Jul 15, 2021

09:02AM EDT Denali Therapeutics To Present Interim Data Phase 1/2 Study Of ETV:IDS For Potential Treatment Of Hunter Syndrome At MPS 2021 Benzinga

09:00AM EDT Denali Therapeutics to Present Interim Data from Phase 1/2 Study GlobeNewswire Inc

Jun 28, 2021

08:12AM EDT Denali Therapeutics Announces Initiation Of Phase 2 Study By Partner Sanofi Of RIPK1-Inhibitor DNL758 In Cutaneous Lupus Erythematosus Patients Benzinga

08:00AM EDT Denali Therapeutics Announces Initiation of Phase 2 Study by GlobeNewswire Inc

Jun 14, 2021

07:52PM EDT at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative PR Newswire

May 25, 2021

06:01AM EDT Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological PR Newswire

May 19, 2021

09:46AM EDT Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening RTTNews

09:04AM EDT Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat PR Newswire

May 18, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 Benzinga

06:37AM EDT UBS Initiates Coverage On Denali Therapeutics with Buy Rating, Announces Price Target of $70 Benzinga

May 3, 2021

08:40AM EDT Denali Therapeutics Q1 EPS $(0.58) Down From $(0.55) YoY, Collaboration Revenue $7.92M Up From $3.60M YoY Benzinga

08:30AM EDT Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights. GlobeNewswire Inc

06:46AM EDT Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End Benzinga

May 1, 2021

09:00AM EDT Denali Therapeutics Presents Positive Results from Phase 1 and GlobeNewswire Inc

Mar 30, 2021

09:30AM EDT Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion PR Newswire

Mar 11, 2021

08:41AM EST Denali Therapeutics Reports Fast Track Designation By FDA To DNL310 For Treatment Of Patients With Hunter Syndrome Benzinga

08:30AM EST Denali Therapeutics Announces Fast Track Designation Granted by GlobeNewswire Inc

Feb 26, 2021

07:52AM EST 10 Biggest Price Target Changes For Friday Benzinga

06:29AM EST HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $95 Benzinga

Feb 25, 2021

04:25PM EST Denali Therapeutics Q4 EPS $1.91 Up From $(0.56) YoY, Sales $316.81M Up From $4.67M YoY Benzinga

07:01AM EST Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire

Feb 12, 2021

08:54AM EST Denali's Enzyme Replacement Therapy Shows Encouraging Biomarker Effects In Early-Stage Hunter Syndrome Study Benzinga

07:45AM EST 'Experts encouraged by Denali's early results in study of Hunter syndrome drug' -STAT News Benzinga

07:33AM EST UPDATE: Denali Phase 1/2 Study Of DNL310 Showed 'Sustained normalization and further decreased levels of CSF glycosaminoglycan heparan sulfate'; Was Generally Well Tolerated With Safety Profile Consistent With Other Enzyme Replacement Therapies Benzinga

07:32AM EST Denali Therapeutics Reports Three-Month Data From Phase 1/2 Study With ETV:IDS (DNL310) In Patients With Hunter Syndrome Benzinga

07:30AM EST Denali Therapeutics Reports Positive Three-Month Data from Phase GlobeNewswire Inc

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 5, 2021

09:03AM EST Denali Therapeutics Says To Present New Data On ETV:IDS For Potential Treatment Of Hunter Syndrome At WORLDSymposium Benzinga

09:00AM EST Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for GlobeNewswire Inc

Jan 11, 2021

08:44AM EST Denali Therapeutics Appoints Nancy Thornberry To Board RTTNews

08:30AM EST Denali Therapeutics Announces Appointment of Nancy Thornberry to GlobeNewswire Inc

Jan 8, 2021

08:34AM EST Denali Therapeutics Highlights Program Progress And Expected Milestones In 2021 For Therapeutic Portfolio In Neurodegeneration Benzinga

08:30AM EST Denali Therapeutics Announces Significant Program Progress and GlobeNewswire Inc

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 16, 2020

12:30PM EST Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $100 Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 12, 2020

08:43AM EST Stocks Trading Near 52-Week Highs Before Open On Thursday, Nov. 12, 2020: NWSA, MNKD, NBACW, CELH, BIOC, DNLI, FIT, THCBW, PANL, PXS, AXTI, RH, THCB, PDD, UPWK, PLUG, UN, SING, PLTR Benzinga

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

07:56AM EST Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $75 Benzinga

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

06:50AM EST HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $80 Benzinga

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

07:32AM EST Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II) Benzinga

07:30AM EST Denali Therapeutics Announces First Human Biomarker Proof of GlobeNewswire Inc

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

06:37AM EST HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $65 Benzinga

Nov 5, 2020

04:19PM EST Denali Therapeutics Q3 EPS $(0.54) Down From $(0.48) YoY, Sales $9.39M Down From $13.60M YoY Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 16, 2020

09:40AM EDT Benzinga's Top Upgrades, Downgrades For October 16, 2020 Benzinga

06:24AM EDT BTIG Downgrades Denali Therapeutics to Neutral Benzinga

Oct 15, 2020

08:16AM EDT Denali Therapeutics To Highlight Progress Across Broad Biotherapeutics Portfolio For Neurodegeneration Enabled By ITs Blood-Brain Barrier TV Platform At Virtual R&D Day Today Benzinga

08:00AM EDT Denali Therapeutics to Highlight Progress Across Broad GlobeNewswire Inc

Oct 7, 2020

08:52AM EDT Denali Therapeutics Closes Collaboration And Share Purchase Agreements With Biogen RTTNews

08:30AM EDT Denali Therapeutics Announces Closing of Collaboration GlobeNewswire Inc

Sep 30, 2020

09:00AM EDT Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time GlobeNewswire Inc

Aug 24, 2020

08:08AM EDT Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $45 Benzinga

Aug 20, 2020

11:41AM EDT HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $45 Benzinga

Aug 7, 2020

04:32PM EDT Denali Therapeutics Q2 EPS $(0.56) Up From $(0.61) YoY, Sales $5.85M Up From $4.20M YoY Benzinga

04:30PM EDT Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights. GlobeNewswire Inc

Aug 6, 2020

02:37PM EDT Mid-Afternoon Market Update: Dow Jumps Over 100 Points; Denali Therapeutics Shares Spike Higher Benzinga

11:31AM EDT Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson's Patients Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Edge Higher; Bristol-Myers Squibb Earnings Top Estimates Benzinga

10:05AM EDT Shares of Denali Therapeutics Inc. (DNLI) are rising more than 35% after the company announced that its LRRK2 inhibitor, DNL151 has met requirements to proceed into further late-stage clinical studies. RTTNews

09:50AM EDT Shares of Denali Therapeutics Inc. (DNLI) were gaining 48 percent in Thursday regular trading, after Biogen Inc. (BIIB) announced a $465 million equity investment as part of a collaboration on Denali's treatment for Parkinson's disease. RTTNews

08:56AM EDT Biogen, Denali To Co-develop Small Molecule Inhibitors Of LRRK2 For Parkinson's Disease. RTTNews

08:03AM EDT Biogen, Denali Therapeutics To Collaborate On LRRK2 Program For Parkinson's Disease, Certain TV Platform-Enabled Programs For Neurodegenerative Diseases; Denali To Receive $560M Upfront Payment, $465M Equity Investment, Potential Milestone Payments Benzinga

Jul 29, 2020

09:01AM EDT Denali Therapeutics Announces Phase 1b Study By Partner Sanofi Of RIPK1-Inhibitor DNL758 In Coronavirus Patients Benzinga

09:00AM EDT Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of GlobeNewswire Inc